News Hub | News Direct

All Industries


Article thumbnail News Release

The Highly Anticipated NILU Hypercar has Arrived!

Nilu

Nilu27, the hypercar brand recently founded by celebrated sports car designer Sasha Selipanov, is thrilled to showcase its first vehicle: the self-titled NILU hypercar. Following a number of social media teasers, which created a stir among the sports car community, the car can finally be revealed in its entirety. The NILU hypercar challenges traditional automotive industry trends. By avoiding electrification, digitalization, and other technological aids, NILU will deliver a raw, unfiltered, uncensored driving experience. Taking inspiration from sources such as ’60s F1 and Le Mans racers, classic Italian design houses, the Bauhaus “form follows function” philosophy, old school American muscle, drift cars, mathematics, and avant garde metal music, NILU’s no-nonsense design is as eclectic as it is original. Sasha’s goal was to create a car with an “inevitable” design: fresh and yet somehow familiar. The resulting NILU exterior, with its tight cross sections and sinuous curves, is functional, lean and aerodynamic. For maximum contrast, it juxtaposes clean sculptural surfaces with its mechanical, exposed and intricately detailed engine bay. True to Bauhaus philosophy, NILU eschews superfluous styling features to celebrate essential functional beauty. The NILU chassis features a bespoke carbon fiber monocoque with lightweight aluminum-alloy tubular subframes. In contrast to “fashionable” composite subframes, the designer deliberately chose a tubular approach to improve access to the drivetrain components while effortlessly facilitating heat extraction and celebrating the mechanical aesthetic. The NILU cabin was designed to provide perfect viewing angles with ideal ergonomics and safety. The designer was able to achieve an incredibly low roofline and compact cabin dimensions without sacrificing comfort. NILU seats two adults in a traditional side-by-side layout with best-in-class ingress and egress made possible by substantial gullwing doors, low sill heights, and fixed, sunken seats, which do not obstruct the door apertures with their side bolsters. The NILU human/machine interface is all about manual, analog controls, inputs and feedback. The only screen is the rear view camera/mirror, which addresses the traditional weakness of mid-engined sports cars: the lack of rearward visibility. The steering wheel’s compact size and perfectly round shape allows for incredibly detailed steering feel and input precision. The wheel is void of switches, buttons and toggles; a testament to the belief that performance driving requires full concentration with zero distractions. Gone are the driving modes, settings and options: NILU controls are both primary and intuitive. For this reason, an open-gate, seven-speed manual transmission celebrates raw, analog driving while adding a safety element with its reverse gear lock-out. Steering wheel, pedal box, headrest, door mirrors and other adjustments are deliberately manual, accessed by gratifying manual levers and switches. The tactile, haptic feedback from cold-touch, machined billet controls was deemed both more engaging and, crucially, safer than navigating through screen menus. PRODUCTION The NILU hypercar is Sasha’s vision in its purest form; a vision he’s been perfecting since 2006. It will initially be available in an extremely limited run with production capped at 15 units. “ My path in the industry has never been about following rules and sticking to norms,” Sasha explained. “I was never afraid to follow my intuition or chase my dreams. Breaking conventions is simply a byproduct. The same is true for NILU – a hypercar that discards current trends and conventions in pursuit of an elevated automotive experience. “Unveiling NILU to the world is a dream come true; a moment so profound it is hard to express in words. The vision was the result of a decades-long search, sleepless nights, years of overthinking and overanalyzing. I was fortunate to learn from and contribute to the industry’s best; now my team and I are thrilled to put all this vision and knowledge into action.” V12 ENGINE Nilu27 has partnered with Hartley Engines in New Zealand to produce one of the most powerful and visually striking naturally aspirated engines in the world. The NILU engine bay is fully exposed, showcasing the beautiful 6.5-liter, 80-degree V12. As NILU will not rely on electrification, it aims to be the world’s most powerful, naturally aspirated hypercar. To achieve this, the V12 will deliver more than 1000 horsepower. And while its large bore and short stroke will make it rev like an electric motor, the even-fire engine will provide the driver with the perfect amount of tactile vibration. The Hartley V12 has a refined combustion area, high-flow ports, and performance-style valve geometry: something OEMs typically cannot accommodate in their compact platforms. The engine also features 12 large, individual throttle bodies for instant throttle response. Another key differentiator for the NILU V12 is its unique “Hot V.” In this configuration, the conventional exhaust and intake positions are swapped around. The setup delivers key advantages when it comes to packaging, heat extraction, and aesthetics. And it has allowed the stunning “snakepit” 12-into-1 exhaust headers to serve as a unique highlight of the exterior design. The entire exhaust system was 3D-printed in Inconel, allowing the complex design to be realized; another unique feature when you consider its dimensions. Mated to the seven-speed CIMA manual transmission, and housed in the ceramic-coated aluminum-alloy subframe, the NILU V12 represents functional beauty at its finest. Nelson Hartley, founder and CEO of Hartley Engines, said, “We’ve been quietly working on the design and layout of our own engine for the last few years, taking inspiration from late ’80s and early ’90s Formula 1 cars. We strove for the kind of engineering that’s raw, endearing, emotional, and sometimes a little crazy. “With Sasha’s wishlist for NILU, we finally found the perfect project to dedicate our time and were able to adapt our development into his Hot V configuration, designing the engine around his chassis layout. “Make no mistake; this is not an OEM engine from another manufacturer converted to the Hot V; this is a bespoke, large bore, short stroke monster. It’s got aggressive cams, aggressive port flow, lightweight components and exotic materials. We want to get a cold sweat every time the V12 starts and revs. It’s fair to say, we’re very excited!" DYNAMICS The NILU hypercar employs a double wishbone, pushrod suspension, with its extremely long wishbones visible from the rear; the length contributing to the exceptionally precise and compliant handling characteristics. A set of Michelin Pilot Sport Cup 2 R tires were fitted, specified at 265/35 R20 front and 325/30 R21 rear. They have been mounted to 10x20” and 13x21” Nilu27 centerlock wheels, which were designed in-house with intricate lightweight detailing to reduce the unsprung weight. The wheels are produced by AppTech in Italy. Carbon-ceramic braking equipment was sourced from Brembo. The Italian company’s GT | BM calipers are fitted front and rear in a custom white finish. The car also has Brembo’s highest performance CCM-R Plus rotors, which deliver outstanding performance and fade resistance. THE FUTURE The initial NILU prototype vehicles and first batch of customer cars will be assembled by Aria Group in Irvine, CA, allowing Nilu27 to ramp-up its own facilities overseas. Nilu27 is simultaneously developing a street homologated version. This variant will be limited to 54 units, four of which will be unique, one-off designs. “We’ve been fascinated by the strong reaction to our social media teasers alone,” said Inna Selipanov, the company’s Co-Founder and COO. “While the world is moving towards electrification, and for very good reason, we firmly believe the timelessness of these cars will not only keep them relevant but they will continue to find a place in the collections of passionate car lovers.” Nilu27 is proud to have the support of industry leaders such as Aerotak, AppTech, Aria Group, Brembo, CIMA, Hartley Engines, Michelin, and Schroth. The car will be unveiled to a select VIP and media group at a private Los Angeles event on August 8. Its public debut will follow on August 15 on the ramp at Pebble Beach in Monterey, California, before appearing on the Concept Lawn at the Pebble Beach Concours d’Elegance on August 18. The NILU hypercar will also debut in CSR Racing 2; the hyper-real mobile racing game from Zynga’s NaturalMotion. Players can experience the high-octane performance and stunning in-game design this November. EDITOR’S NOTE Images for editorial use are available here: https://www.dropbox.com/scl/fo/slb7tdet19fb5pomdq8vo/AJPBTh72JpXxQSJDFwZA6JI?rlkey=4cn745k7vb2sxs4fmlfwwk5gb&dl=0 Please contact us if high-resolution images are required for print. A NILU video is available to view and share here: https://youtu.be/2gbQEQwedr8 ABOUT Nilu27 Founded in 2024 by Sasha and Inna Selipanov, Nilu27 is on a mission to produce quintessential sports cars that will withstand the test of time. With a primary focus on a visceral driving experience, the company’s purpose is to celebrate all elements of the car that engage the senses, which means divorcing from technology in certain instances. We’re car people; we build cars for people who love cars. For more information, please visit nilu27.com Contact Details Greg Emmerson, The ID Agency greg@theidagency.com Company Website https://www.nilu27.com/

August 07, 2024 05:55 AM Pacific Daylight Time

Image
Article thumbnail News Release

Iteris And Sumitomo Electric Introduce Advanced Pedestrian Safety Solution To Reduce Fatalities In North America

Benzinga

By Austin DeNoce, Benzinga On Jun. 11, Iteris Inc. (NASDAQ: ITI), a leading technology ecosystem for smart mobility infrastructure management, announced an exclusive agreement with Sumitomo Electric Industries (SEI) to bring the Sumitomo Pedestrian Detection sensor to the U.S. market. This collaboration aims to integrate SEI’s advanced radar technology into the Iteris ClearMobility Platform in order to save pedestrian lives and provide valuable data that enable additional improvements in mobility management. Technology Integration And Features The Sumitomo Pedestrian Detection sensor uses cutting-edge radar technology to detect pedestrians with high accuracy. Since its launch in 2017, this sensor has helped reduce pedestrian-vehicle conflicts in various regions of Japan, particularly protecting vulnerable populations like the elderly. By incorporating this technology into the ClearMobility Platform’s ecosystem, Iteris will strengthen its industry-leading transportation safety solutions portfolio and gain access to more granular pedestrian data to improve its comprehensive mobility data set. The sensor’s advanced features include its ability to operate effectively in all weather and lighting conditions, from sunshine to total darkness, thanks to its 24 GHz millimeter-wave radar technology. Proprietary algorithms also enable it to track pedestrians even when they are obscured by other vehicles, covering a wide detection area suitable for various intersection and midblock configurations. The sensor will be integrated into Iteris’ Vantage PedSafe solution, including real-time analytics through Iteris’s ClearGuide software, which provides insights into pedestrian activity and helps identify unsafe areas. A Pedestrian Safety System Vantage PedSafe, a key component of Iteris’s comprehensive detection solutions, is designed to protect vulnerable road users (VRUs) in diverse conditions, making it ideal for high-traffic areas such as intersections, school zones, university campuses, transportation hubs and entertainment venues. This advanced system utilizes cutting-edge sensors and analytics to monitor pedestrian movements and optimize traffic signal timings, ensuring safer crossings. Vantage PedSafe can activate dynamic street lighting, LED beacons and message signs to alert drivers of pedestrians, enhancing visibility and awareness. Finally, the system broadcasts safety warnings to connected vehicles and optimizes traffic operations by adjusting signal timing based on real-time pedestrian detection. By integrating these innovative features, Vantage PedSafe significantly reduces accidents while improving the overall flow of traffic, exemplifying Iteris’s commitment to pedestrian safety and modern transportation solutions. Transportation Equality And Vision Zero Vision Zero is another leg of this push for enhanced pedestrian safety, aiming to eliminate traffic fatalities and serious injuries partly through addressing issues with transportation equity in underserved communities. Vantage PedSafe looks at the higher pedestrian fatality rates in lower-income areas and helps agencies secure safety-related grants by demonstrating effective safety improvements. In 2022, pedestrian fatalities in the U.S. reached the highest level in 40 years, with 7,508 deaths, 76% of which occurred in dark conditions. Additionally, the rate of fatalities was nearly double in lower-income areas. This underscores the critical need for advanced pedestrian detection solutions like those provided by Iteris. If implemented, thousands of lives could be saved each year, particularly in lower-income communities. A Safer Future For Pedestrians Iteris is continuously monitoring, visualizing and optimizing mobility infrastructure to ensure that roads are safe, travel is efficient and communities can thrive. Various private-sector enterprises and thousands of public agencies already rely on its solutions, making it a trusted leader in smart mobility infrastructure management. Ultimately, this latest integration by Iteris, combined with its innovative in-house pedestrian safety technology, promises to create safer environments and reduce traffic fatalities across the U.S. Featured photo by Steve DiMatteo on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

August 07, 2024 08:30 AM Eastern Daylight Time

Image
Article thumbnail News Release

Powerful Connections – This Tech Company Streamlines Influencer Marketing

Benzinga

By Johnny Rice, Benzinga Ted Murphy, CEO of IZEA Worldwide (NASDAQ: IZEA), was recently a guest on Benzinga’s All-Access. IZEA Worldwide is a marketing technology company providing software and professional services that enable brands to collaborate and transact with the full spectrum of today’s top social influencers and content creators. The company serves as a champion for the growing creator economy, enabling individuals to monetize their content, creativity, and influence. Murphy spoke about the powerful, bespoke connections influencers can make with their audiences and the value that creates for brands. Learn more here: Featured photo by Karsten Winegeart on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

August 07, 2024 08:30 AM Eastern Daylight Time

Video Image
Article thumbnail News Release

Unique Canadian Mortgage Market Presents $2.2 Trillion Opportunity For Pineapple Financial

RazorPitch PAPL

Canada has a unique mortgage market that requires holders to refinance after every five years. If you're an investor looking to capitalize on this opportunity, one little-known company offers the perfect way to do so. Pineapple Financial Inc. (NYSE American:PAPL) is a digital mortgage company focused on providing Canadian mortgage brokers with the systems, tools, and technologies they need to provide home buyers and mortgage seekers with a more digital customer experience. The company was established about 8 years ago after realizing that the real opportunity was in digitizing the old and archaic mortgage origination industry, which was very manual and paper-heavy. The solution was to build a full end-to-end cloud enterprise management platform for everything from lead inception to customer marketing automation, profile building, segmentation, data collection, document collection, SWOT analysis, compliance, payroll, and retention, all within a single ecosystem and environment. Pineapple is also the first Canadian company to integrate artificial intelligence and data analytics into the mortgage origination process, making it well positioned to capitalize on the refinancing cycle. That is because the company’s technology is designed and geared towards Canadian mortgage brokers, which is a very fast-growing channel of origination. A quick look at half of all mortgages that Canadians originate reveals that over 75% are first-time home buyers, and over 70% of buyers under the age of 45 prefer to utilize a mortgage broker. The company expects that these growing demographics will prefer using digital channels such as Pineapple’s platform, which is reaffirmed when we look at other areas of the world. For instance, in Australia, Europe, and the US, over 80% of mortgage originations are done through the mortgage broker channel. This means that Pineapple has plenty of room to grow as the market organically grows in Canada. To put the opportunity in context, consider this: There is about $2.2 trillion of outstanding mortgage debt in Canada. What makes the Canadian mortgage market unique compared to other markets is the fact that it doesn't offer long-term mortgages. Instead, it has 1–5-year terms, after which the mortgage will come up for maturity or renewal. This is where Pineapple comes in, as it will have the opportunity to reservice that customer, and these continually servicing opportunities with each cycle provide the company with tremendous potential to continue growing revenue and the business. The exciting thing is that 73% of all current Canadian mortgages will be coming up for maturity within the next 3 years or by the end of 2027, which translates to about $1.6 trillion of potential originations. In addition to that, Canada has the fastest-growing population in the world. The country grew its population by 3.7% in the last year and will be welcoming 1.2 million immigrants in the next 12 months. Statistically, 80% of new immigrants in Canada will purchase a home within 3 years of arriving. Now couple that with about 4 million Canadians who are entering the home buying stage of their lives, and it's clear to see that Pineapple Financial Inc. (NYSE American:PAPL) has a tremendous growth opportunity. Right now, Pineapple is funding about $2.5 billion per year in mortgage originations out of a potential $700–$800 billion per year of originations, which further reaffirms just how significant the company’s potential for growth and scaling is. Pineapple’s unique business model gives it a number of competitive advantages over existing mortgage broker products. First, it has chosen to digitally and technologically enable a pre-existing distribution channel like mortgage brokers that already have embedded relationships within various communities across the country. This drastically cuts down on acquisition costs and further reduces the time needed to build volumes. Additionally, Pineapple has built a fully integrated system, whereas a lot of solutions on the market are focused on building solutions to one piece of the mortgage processing lifecycle. Pineapple end-to-end solution means that all areas of the mortgage origination processing life cycle are housed within one ecosystem, so the data entry, data integrity, and efficiency of the information are much more accurate, concise, and usable. This business model has been validated by the market, as illustrated by the fact that it became profitable within the first four years of its operations. Investors went on to reaffirm their confidence in the company after Pineapple closed its first financing in April 2021. At that time, the company had about 100 brokers on its platform, funded just under $1 billion per year, and was only operational in Ontario. The company had tremendous buy-in from the industry and successfully raised $9.3 million to begin scaling the business. Since then, the company has expanded to every province across Canada, is fully coast-to-coast, has over 700 brokers on the platform, and is funding over $2.5 billion in mortgages. In November last year, Pineapple Financial Inc. (NYSE American:PAPL) IPO’d, raising $3.5 million and listing on the NYSE. At the same time, the company brought in a strategic long-term capital partner who would be focused on ensuring that the company is capitalized both in the short term and in the long term by being an anchor institutional investor. Pineapple has a market capitalization of about $7.2 million, which appears to be undervalued by the market considering the revenue and efficiency of the business. We believe that the company has significant upside potential once more investors recognize the multiple tailwinds driving growth. Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by Pineapple Financial to assist in the production and distribution of this content. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details RazorPitch Inc. Mark McKelvie +1 585-301-7700 mark@razorpitch.com Company Website http://razorpitch.com

August 07, 2024 05:00 AM Eastern Daylight Time

Article thumbnail News Release

HTX Releases July Performance Report: 24-Hour Trading Volume Rises to Top 2 Worldwide for the Third Time, Achieving Steady Progress

HTX

The HTX team has recently released its performance report for July, sharing key achievements and milestones with users. The report updates both new and existing users on HTX's significant progress across various fronts, including rankings by external institutions, new asset listings, HTX Ventures' investment projects and participation in activities, HTX's 11th-anniversary events, liquidity pledge received by HTX DAO, as well as security and customer service data. Through this disclosure, HTX expresses gratitude to its users for their continued support and trust. HTX Ranks Second Globally in 24-Hour Trading Volume and Lists Many Quality Assets Despite volatile fluctuations in the crypto market, HTX saw an 11.3% increase in trading volume in July compared to the previous month. According to CoinGecko data on July 24, HTX's 24-hour trading volume reached $2.8 billion, securing second place globally. This achievement marks the third time this year that HTX has attained a top-two position, reflecting its steady progress in climbing the rankings. HTX expanded its asset offerings in July by listing 15 cryptos, including PIXFI, A8, LRDS, and AVAIL, synchronizing their debut with other exchanges like Coinbase. Following the listing, AVAIL's price skyrocketed by 90%, while FIGHT's price surged by 60%. NEIRO, playfully dubbed "DOGE 2.0", was listed at the end of July. HTX Ventures Invests in Two Projects and Participates in EthCC; HTX's 11th Anniversary Events Officially Kick Off HTX Ventures announced in July that it had invested in Lombard and Redstone. The HTX Ventures investment team attended side events at EthCC in Brussels, where they shared insights on "Restaking Development" and "How to Successfully Launch a Web3 Ecosystem". Additionally, they published an industry research paper across various media platforms. HTX Ventures will keep exploring new frontiers to create more opportunities and deliver greater value to the platform users. Dedicated to fostering the long-term growth of the Ethereum ecosystem, it consistently seeks technologies and projects that improve the experience of crypto users. In July, HTX also kicked off its 11th anniversary event—the Battle of Glory for KOLs. Participants who register for the event can compete for a 200,000 USDT prize pool. At the same time, HTX has launched an 11th Anniversary Appreciation Plan for Existing users, offering a refund of account management fees totaling tens of millions of dollars. As HTX marks its 11th anniversary, a lineup of events to thank users for their continuous support is now underway. Please log in to the HTX platform for more information. HTX Intensifies Security Efforts, Ensuring the Protection of User Assets While Providing Quality Services In July, HTX continued to strengthen its security measures by sending 292,937 security alerts to users and combating 5 phishing websites and fake app download sites. We intercepted 4 transactions to scam addresses, recovering 100,000 USDT in lost funds. We also handled 12 incidents involving stolen assets from external sources and helped users freeze over 130,000 USDT in stolen funds. Additionally, we blacklisted 7,118 new addresses, intercepting 35 deposits amounting to about 650,000 USDT. The HTX security team is fully committed to safeguarding user assets through concrete efforts and effective measures. Additionally, HTX DAO announced this month that the Liquidity Pledge for Q2 2024 has been completed. A total of $30.5 million was pledged and burned during this period. In Q2 2024, HTX DAO received ecosystem liquidity pledges totaling $21.5 million, bringing the cumulative amount to $42.5 million. HTX also completed $10 million in compensation for users affected by the pGALA incident. The package covers payouts, platform benefits, and Gala nodes. The platform remains fully dedicated to protecting the interests of its users. Throughout July, HTX's customer service team assisted 38,800 users and effectively addressed 61,646 inquiries and support tickets. The issues mainly involved user account security and P2P trading problems. Over 83% of users have expressed positive feedback. In the face of recent market turbulence, HTX will steadfastly stand by users through the ups and downs of the market and move forward together. The platform is about to celebrate its 11th anniversary and will take the opportunity to thank users for their unwavering trust and support over the years. The "user-first" principle has always been central to HTX. The platform continues to strive toward enhancing the quality of its services with the goal of providing users with the best possible trading experience. Looking ahead, the HTX team will publish performance reports on a monthly basis to ensure full transparency for its users. These reports will cover key metrics such as operational data, asset performance, investment results, security measures, and customer service. With sincerity, HTX aims to forge an even stronger bond with its user community, working together to create a better future. About HTX Founded in 2013, HTX has evolved over a decade from a simple cryptocurrency exchange to a comprehensive blockchain business ecosystem. This expansion covers a wide range of services including digital asset trading, financial derivatives, wallets, research, investments, incubation, and more. As a world-leading portal to Web 3.0, HTX is committed to a growth strategy focused on global expansion, ecological prosperity, wealth effect, and safety and compliance. This approach enables us to offer comprehensive, safe, and reliable services and value to virtual currency enthusiasts around the world, reinforcing our position as a global gateway to Web3. Contact Details EE glo-media@htx-inc.com Company Website https://www.htx.com/

August 06, 2024 02:19 PM Eastern Daylight Time

Article thumbnail News Release

Copper Property CTL Pass Through Trust Schedules Live Call to Discuss Recent Financial and Operating Results

Copper Property CTL Pass Through Trust

Copper Property CTL Pass Through Trust (“the Trust”) announced today that it will host a live conference call on Tuesday, August 13, 2024 at 12:00 pm Eastern Time. Members of the Trust’s management team will discuss its recent financial and operating results as reflected in the Trust’s monthly report for the period ended July 31, 2024, and Form 10-Q for the period ended June 30, 2024, both of which are expected to be filed prior to the call. The conference call will include a question and answer (Q&A) session. Additional information, including the Trust’s Monthly and Quarterly Reports, as well as other filings with the Securities and Exchange Commission (“SEC”) can be accessed via the Trust’s website at www.ctltrust.net. Conference Call Details: DATE: Tuesday, August 13, 2024 TIME: 11:00 am CDT | 12:00 pm EDT DIAL-IN: U.S. & Canada Toll Free: (877) 841-2983 or International (215) 268-9893 WEBCAST: www.ctltrust.net via the Investor Relations Section or click here to access REPLAY (Available for 30 days): U.S. & Canada Toll Free: (877) 660-6853 / International: (201) 612-7415 Conference ID#: 13748365 Telephone Replays will be made available approximately 3 hours after the conference end time. Participants will be required to state their name and company upon accessing the replay. About Copper Property CTL Pass Through Trust Copper Property CTL Pass Through Trust (the “Trust”) was established to acquire 160 retail properties and 6 warehouse distribution centers (the “Properties”) from J.C. Penney as part of its Chapter 11 plan of reorganization. The Trust’s operations consist solely of owning, leasing and selling the Properties. The Trust’s objective is to sell the Properties to third-party purchasers as promptly as practicable. The Trustee of the trust is GLAS Trust Company LLC. The Trust is externally managed by an affiliate of Hilco Real Estate LLC. The Trust is intended to be treated, for tax purposes, as a liquidating trust within the meaning of United States Treasury Regulation Section 301.7701-4(d). For more information, please visit https://www.ctltrust.net/. Forward Looking Statement This news release contains certain “forward-looking statements”. All statements other than statements of historical fact are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward looking terminology such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “our vision,” “plan,” “potential,” “preliminary,” “predict,” “should,” “will,” or “would” or the negative thereof or other variations thereof or comparable terminology and include, but are not limited to, the Trust’s expectations or beliefs concerning future events and stock price performance. The Trust has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Trust believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond its control. These factors, including those discussed in the Trust’s Registration Statement on Form 10 filed with the Securities and Exchange Commission (the “SEC”), may cause its actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by these forward-looking statements. For a further list and description of such risks and uncertainties, please refer to the Trust’s filings with the SEC that are available at www.sec.gov. The Trust cautions you that the list of important factors included in the Trust’s SEC filings may not contain all of the material factors that are important to you. In addition, in light of these risks and uncertainties, the matters referred to in the forward-looking statements contained in this news release may not in fact occur. The Trust undertakes no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as otherwise required by law. Contact Details Jessica Cummins +1 847-313-4755 jcummins@hilcoglobal.com Company Website https://ctltrust.net/about/default.aspx

August 06, 2024 12:35 PM Eastern Daylight Time

Article thumbnail News Release

Alzamend Neuro Partners with Massachusetts General Hospital for Phase II Trial of AL001 involving Patients with Bipolar Disorder and Alzheimer's Disease

MarketJar

Mental health issues are on the rise, affecting almost 60 million US adults and more than 970 million people worldwide. 1 Rising cases has led to an uptick in new treatments moving through the clinical stages, including Alzamend Neuro, Inc. (NASDAQ:ALZN), which is focused on developing next-generation treatments for Alzheimer’s disease, bipolar disorder (BD), major depressive disorder (MDD), and post-traumatic stress disorder (PTSD). Among its promising pipeline, AL001 stands out as a potential game-changer for bipolar disorder treatment. Alzamend Neuro 's AL001, a patented ionic cocrystal technology, aims to deliver lithium in a way that reduces toxicity while maintaining therapeutic efficacy by combining lithium, salicylate, and L-proline. Alzamend Neuro is rapidly advancing treatments for mental health disorders, potentially accelerating clinical phase progress due to the successes of AL001 in a Phase I and Phase IIA clinical trials for the treatment of Alzheimer’s. In 2023, the company filed IND applications for Phase IIA Clinical Trials of AL001 for Bipolar Disorder, MDD and PTSD. By the end of 2023, the FDA granted approval for these studies via “Study may proceed” letters. Alzamend Neuro Partners with MGH for Phase II Trial of Next-Generation Lithium Therapeutic Drug Candidate for Bipolar Disorder On August 6th, Alzamend Neuro, Inc. (NASDAQ:ALZN) announced a partnership with Massachusetts General Hospital (MGH) to conduct a Phase II clinical trial of AL001 for treatment of patients with bipolar disorder. MGH, the primary clinical education and research facility of Harvard Medical School, is the world's largest hospital-based research program. Dr. Ovidiu Andronesi MD, PhD, Associate Professor of Radiology at Harvard University and Director of Multinuclear Metabolic Imaging at the Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, will lead the study as the Principal Investigator. The trial will compare AL001 to a marketed lithium carbonate product, focusing on bioavailability and brain distribution of lithium, with the goal of establishing AL001's safe, effective, and tolerable dosing requirements. AL001 is designed to offer the therapeutic benefits of traditional lithium salts while minimizing their toxic side effects. This head-to-head study will measure lithium levels in the brain and structures of bipolar disorder patients, building on mouse studies that suggest AL001 can achieve therapeutic benefits at lower doses. The study will also leverage brain imaging to predict the efficacy and safety of AL001 compared to existing lithium treatments. Alzamend Neuro 's previous Phase IIA studies of AL001 in Alzheimer's patients and healthy subjects have demonstrated a benign safety profile, identifying a candidate dose unlikely to require therapeutic drug monitoring (TDM). This is a significant advancement, as current lithium treatments require rigorous monitoring due to their narrow therapeutic window and potential toxicity. “We are elated to partner with Massachusetts General Hospital and Dr. Andronesi in this pivotal study for our lead therapeutic candidate AL001,” said Alzamend Neuro, Inc. (NASDAQ:ALZN) CEO Stephan Jackman, “If we can develop a next-generation lithium product (AL001) with an improved safety profile and enhanced biodistribution in the brain that would not routinely require therapeutic drug monitoring (TDM), it would constitute a major improvement over current lithium-based treatments and positively impact the 7+ million Americans afflicted with bipolar disorder. We look forward to providing more details regarding study timelines and market opportunity in the near future.” This innovation has the potential to positively impact the over 7 million Americans living with bipolar disorder. Further details about the study timelines and market potential will be shared soon. Alzamend Neuro to Conduct a Phase II Clinical Trial of AL001, involving Patients with Alzheimer’s Disease Alzamend Neuro, Inc. (NASDAQ:ALZN) also just announced a collaboration with Massachusetts General Hospital (MGH) to conduct A Phase II clinical trial for AL001, for the potential treatment of Alzheimer's disease. This trial will involve both Alzheimer’s patients and healthy subjects to compare the bioavailability and brain distribution of AL001 versus a marketed lithium carbonate product. The trial, which will also be led by Dr. Ovidiu Andronesi of Harvard University, aim to establish AL001's safe, effective, and tolerable dosing requirements. The potential to avoid the need for therapeutic drug monitoring (TDM) is also significant, as it could simplify treatment regimens and improve patient compliance. By potentially offering a safer and more effective alternative to traditional lithium treatments, AL001 could revolutionize how Alzheimer's disease is managed. The ability to measure lithium levels directly in the brain and brain structures using advanced imaging techniques will provide invaluable insights into the drug’s efficacy and safety. This approach not only enhances our understanding of how AL001 works but also supports its potential approval through a Section 505(b)(2) pathway with the FDA. If successful, the trial could pave the way for a new era in Alzheimer's treatment, providing hope for millions of patients and their families. Financial Support for Clinical Trial In addition to this groundbreaking partnership, Alzamend Neuro, Inc. (NASDAQ:ALZN) recently secured the first two tranches of a $25 million Series A purchasing agreement. This investment supports the advancement of Alzamend 's clinical trial and the development of next-generation treatments for Alzheimer’s, bipolar disorder, MDD, and PTSD. CEO Stephan Jackman emphasized the company's dedication to advancing clinical milestones and revolutionizing lithium-based therapies for millions affected by these conditions. Click here for more information about Alzamend Neuro, Inc. (NASDAQ:ALZN). [1] https://www.who.int/health-topics/mental-health#tab=tab_2 Disclaimer  1) The author of the Article, or members of the author’s immediate household or family, do not own any securities of the companies set forth in this Article. The author determined which companies would be included in this article based on research and understanding of the sector.  2) The Article was issued on behalf of and sponsored by, Alzamend Neuro, Inc. Market Jar Media Inc. was paid $1,500 for the production and publishing of this article by Alzamend Neuro, Inc.’s Digital Marketing Agency of Record (Native Ads Inc.). Additional details relating to Market Jar Media Inc.’s engagement by Alzamend Neuro, Inc.’s Digital Marketing Agency of Record (Native Ads Inc.) are set out in https://pressreach.com/disclaimer-alzn.  3) Statements and opinions expressed are the opinions of the author and not Market Jar Media Inc., its directors or officers. The author is wholly responsible for the validity of the statements. The author was not paid by Market Jar Media Inc. for this Article. Market Jar Media Inc. was not paid by the author to publish or syndicate this Article. Market Jar has not independently verified or otherwise investigated all such information. None of Market Jar or any of their respective affiliates, guarantee the accuracy or completeness of any such information. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Market Jar Media Inc. requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Market Jar Media Inc. relies upon the authors to accurately provide this information and Market Jar Media Inc. has no means of verifying its accuracy.  4) The Article does not constitute investment advice. All investments carry risk and each reader is encouraged to consult with his or her individual financial professional. Any action a reader takes as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Market Jar Media Inc.'s terms of use and full legal disclaimer as set forth here. This Article is not a solicitation for investment. Market Jar Media Inc. does not render general or specific investment advice and the information on pressreach.com should not be considered a recommendation to buy or sell any security. Market Jar Media Inc. does not endorse or recommend the business, products, services or securities of any company mentioned on pressreach.com.  5) Market Jar Media Inc. and its respective directors, officers and employees hold no shares for any company mentioned in the Article.  6) This document contains forward-looking information and forward-looking statements, within the meaning of applicable Canadian securities legislation, (collectively, “forward-looking statements”), which reflect management's expectations regarding Alzamend Neuro, Inc.’s future growth, future business plans and opportunities, expected activities, and other statements about future events, results or performance. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to Alzamend Neuro, Inc.’s industry; (b) market opportunity; (c) Alzamend Neuro, Inc.’s business plans and strategies; (d) services that Alzamend Neuro, Inc. intends to offer; (e) Alzamend Neuro, Inc.’s milestone projections and targets; (f) Alzamend Neuro, Inc.’s expectations regarding receipt of approval for regulatory applications; (g) Alzamend Neuro, Inc.’s intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h) Alzamend Neuro, Inc.’s expectations with regarding its ability to deliver shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute Alzamend Neuro, Inc.’s business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c) Alzamend Neuro, Inc.’s ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) Alzamend Neuro, Inc.’s ability to enter into contractual arrangements with additional parties; (e) the accuracy of budgeted costs and expenditures; (f) Alzamend Neuro, Inc.’s ability to attract and retain skilled personnel; (g) political and regulatory stability; (h) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (i) changes in applicable legislation; (j) stability in financial and capital markets; and (k) expectations regarding the level of disruption to as a result of CV-19. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of Alzamend Neuro, Inc. to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a) Alzamend Neuro, Inc.’s operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises such as CV-19 may adversely impact Alzamend Neuro, Inc.’s business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing Alzamend Neuro, Inc.’s business operations (e) Alzamend Neuro, Inc. may be unable to implement its growth strategy; and (f) increased competition.  Except as required by law, Alzamend Neuro, Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Neither does Alzamend Neuro, Inc. nor any of its representatives make any representation or warranty, express or implied, as to the accuracy, sufficiency or completeness of the information in this document. Neither Alzamend Neuro, Inc. nor any of its representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this document by you or any of your representatives or for omissions from the information in this document.  7) Any graphs, tables or other information demonstrating the historical performance or current or historical attributes of Alzamend Neuro, Inc. or any other entity contained in this document are intended only to illustrate historical performance or current or historical attributes of Alzamend Neuro, Inc. or such entities and are not necessarily indicative of future performance of Alzamend Neuro, Inc. or such entities.  8) Investing is risky. The information provided in this article should not be considered as a substitute for professional financial consultation. Users should be aware that investing in any form carries inherent risks, and as such, there is a possibility of losing some or all of their investment. The value of investments can fluctuate significantly within a short period, and investors must understand that past performance is not indicative of future results. Additionally, users should exercise caution as transactions involving investments may be irreversible, even in cases of fraud or accidental actions. It is crucial to acknowledge that rapidly evolving laws and technical issues can have adverse effects on the usability, transferability, exchangeability, and value of investments. Furthermore, users must be cognizant of potential security risks associated with their investment activities. Individuals are strongly encouraged to conduct thorough research, seek professional advice, and carefully evaluate their risk tolerance before engaging in any investment endeavors. Market Jar Media Inc. is neither an investment adviser nor a broker-dealer. The information presented on the website is provided for informative purposes only and is not to be treated as a recommendation to make any specific investment. No such information on pressreach.com constitutes advice or a recommendation. Contact Details James Young +1 800-340-9767 campaigns@pressreach.com Company Website https://pressreach.com

August 06, 2024 11:45 AM Eastern Daylight Time

Image
Article thumbnail News Release

Bluepeak to Invest More Than $31 Million to Bring Fiber Optic Internet to the Cities of Stephenville, Mineral Wells, and Ennis

Bluepeak

Bluepeak is investing more than $31 million to expand its fiber-to-the-home (FTTH) network to the cities of Stephenville, Mineral Wells, and Ennis, Texas. The network expansion will bring a new fast, affordable, reliable fiber internet option to more than 22,000 homes and businesses starting in 2025. “We promised to build out our network in underserved areas, reaching more new locations with fiber in 2025,” said Bluepeak CEO, Rich Fish. “This latest network expansion actively delivers on that commitment in areas where connectivity will make a dramatic impact to the local economy. In all three of these markets, we aim to empower local businesses, support educational advancements, and facilitate seamless connectivity for residents.” “Reliable access supports the core needs of every community, both homes and businesses, serving as a catalyst for growth, innovation, and opportunity,” said Mike Harry, Chief Business Development Officer of Bluepeak. “We look forward to continuing to work closely with local leaders and community members to ensure our services are contributing positively to their everyday lives.” Since 2021, Bluepeak has been dramatically improving broadband options by bringing fast, dependable, fiber internet with transparent pricing to residents of Oklahoma, Wyoming, South Dakota, North Dakota and soon-to-be Texas. With Bluepeak Fiber Internet service, customers get fiber-fast speeds, equal upload and download speeds and whole-home WiFi. Bluepeak service features all-in pricing, where the price on the website is the price on the bill, with a minimum service tier of 1 gigabit-per-second (Gbps). Homes can get up to 5 Gbps and businesses 10 Gbps and beyond. Each fiber internet speed package includes Wi-Fi powered by eero, along with the added value of eero Secure, which protects devices from online threats, ads and allows for customized content filtering. Bluepeak's fiber network provides reliable connectivity and the bandwidth to connect more devices for internet, streaming, gaming and more. Ultimately, Bluepeak service increases broadband competition for internet consumers by offering an advanced fiber connection in communities where choices have traditionally been very limited. Those in Stephenville, Mineral Wells, or Ennis interested in more information on Bluepeak service availability and details on the construction process can sign up for updates by entering their service address at mybluepeak.com. About Bluepeak Bluepeak is a new kind of internet provider bringing fast, reliable, affordable internet to places that have needed better options for too long. The company has roots serving Great Plains and Midwest communities going back more than 30 years. As the need for internet in the region has evolved, so has Bluepeak, upgrading and expanding service in South Dakota, southwest Minnesota, Oklahoma, Wyoming, North Dakota, and soon-to-be Texas, with the newest cutting-edge technology. These expansion efforts include multi-million-dollar infrastructure projects, community involvement and growth through local hires. Bluepeak is earning the trust of customers and businesses through simple, affordable offerings, responsive, reliable customer service and transparent pricing. The company’s unique approach to delivering internet service has earned Bluepeak accolades for customer satisfaction, network performance, workplace culture and meaningful community partnerships. Visit www.mybluepeak.com to learn more. Contact Details Parnomi PR, on behalf of Bluepeak Angie Knight +1 574-208-9090 media@parnomi.com Company Website https://www.mybluepeak.com

August 06, 2024 09:00 AM Mountain Daylight Time

Article thumbnail News Release

Citius Pharmaceuticals To Receive 65 Million Shares Of TenX Keane For Merger Of Citius Oncology

Benzinga

By Meg Flippin, Benzinga Citius Pharmaceuticals Inc. (NASDAQ: CTXR), a late-stage biopharmaceutical company, is progressing with its focus on unlocking value for investors by announcing that shareholders of TenX Keane Acquisition (NASDAQ: TENK), a publicly traded special purpose acquisition company, have voted to approve the previously announced business combination between TenX Keane and Citius Pharma’s oncology subsidiary. The newly combined public company will continue to trade on the Nasdaq stock exchange and is to be renamed Citius Oncology, Inc. In October, Citius announced it was spinning out its wholly-owned oncology unit to form Citius Oncology, a standalone publicly traded entity. Under the terms of the deal, Citius Pharma is getting 65.6 million shares of common stock of Citius Oncology, which would represent approximately 90% of the newly public company. As part of the transaction, Citius Pharma will contribute $10 million in cash to Citius Oncology. An additional 12.75 million existing options will be assumed by Citius Oncology. At closing, any cash remaining in TenX’s trust account along with the cash provided by Citius Pharma will be contributed to Citius Oncology for working capital and general corporate purposes of Citius Oncology following the transaction. Unlocking Significant Value Citius previously stated that the SPAC deal is expected to unlock significant value for Citius shareholders by separating the oncology business, potentially leading to increased access to capital markets and further development of new applications and additional intellectual property. It also underscores Citius’ strategy to purchase assets, develop them and bring them to market and then unlock shareholder value. First Out Of The Gate: LYMPHIR Citius Oncology will serve as a platform to develop and commercialize novel targeted oncology therapies. The first to go to market will be LYMPHIR, a recombinant fusion protein designed to treat T-cell lymphomas. Citius said the deal is expected to provide Citius Oncology with improved access to the public equity markets and thereby facilitate the commercialization of LYMPHIR and position the company to explore additional value-creating opportunities more fully. The drug agent LYMPHIR combines the interleukin-2 (IL-2) receptor binding domain with diphtheria toxin fragments. The agent specifically binds to IL-2 receptors on the cell surface, causing diphtheria toxin fragments that have entered cells to inhibit protein synthesis. In 2011 and 2013, the FDA granted orphan drug designation to LYMPHIR for the treatment of peripheral T-cell lymphoma (PTCL) and Cutaneous T-cell lymphoma (CTCL). In 2021, Citius acquired an exclusive license with rights to develop and commercialize LYMPHIR in all markets except for Japan and certain other parts of Asia. In March this year, the FDA accepted Citius’s Biologics License Application (BLA) for LYMPHIR with a decision expected on August 13, 2024, the FDA's assigned Prescription Drug User Fee Act (PDUFA) action date. If approved, Citius is preparing for LYMPHIR commercialization later this year. “The reason we are doing this is acquire a Nasdaq listing by having the SPAC acquire the assets and at the same time it enables us to do something to prevent dilution for shareholders,” said Leonard Mazur, CEO of Citius in a recent interview with Benzinga. The CEO counts himself as one of the shareholders. He has invested $22.5 million of his own money in the business. “During the first year on the market we will be profitable. All that benefits Citius shareholders,” he said. Featured photo by National Cancer Institute on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

August 06, 2024 10:45 AM Eastern Daylight Time

Image
1 ... 96979899100 ... 3773